Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR

NCT03676504 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

68

Enrollment

OTHER

Sponsor class

Conditions

Acute Lymphoblastic Leukemia, Adult
Acute Lymphoblastic Leukemia, Pediatric
Chronic Lymphocytic Leukemia
Diffuse Large B Cell Lymphoma
Follicular Lymphoma
Mantle Cell Lymphoma

Interventions

BIOLOGICAL: CD19.CAR T Cells
DRUG: Fludarabine
DRUG: Cyclophosphamide

Sponsor

University Hospital Heidelberg